phase readout
saveNCT07006727: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE1. Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
view source ↗
comments(0)
5-min edit window · permanent after that